March 17, 2021
by Kevin Hennegan

How to know when to submit an IND

Submitting an Investigational New Drug (IND) application to the US FDA is a significant step in the development of a new drug or biologic product. But how do you know when it is time to begin the process of preparing and submitting your IND?  Sponsors ask us this question every day.

Solve the Mystery - Learn How to Know if You Are Ready to Submit your IND to FDA
Veristat experts explore the minimum required content for an IND submission and the strategic considerations for developing more than the minimum necessary data before filing an IND. Hear from regulatory experts responsible for dozens of IND submissions who cover considerations such as selecting a target indication, seeking pre-IND advice from FDA, deciding whether to use US or non-US sites for early clinical research and more. The direction provided will help you determine whether you are ready to submit your IND and take the next step in the development of your product.
 
View the webinar replay to help you better understand:
  • Drug development overview
  • Purpose of an IND
  • When do you have enough data?
  • Value of a pre-IND meeting
Kevin Hennigan is a senior regulatory strategist at Veristat.


 
×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.